OncoMatch/Clinical Trials/NCT06931626
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Is NCT06931626 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including NMS-03305293 and Temozolomide for small cell lung cancer.
Treatment: NMS-03305293 · Temozolomide — This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Metastatic disease required
must have failed prior front-line platinum-based therapy including immune therapy with relapse within 6 months followed by failed tarlatamab therapy, if available and appropriate, and no more than 3 total prior lines of systemic therapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — front-line
must have failed prior front-line platinum-based therapy including immune therapy with relapse within 6 months
Must have received: immune therapy — front-line
must have failed prior front-line platinum-based therapy including immune therapy with relapse within 6 months
Must have received: tarlatamab (tarlatamab)
failed tarlatamab therapy, if available and appropriate
Cannot have received: wide-field radiotherapy affecting at least 20 percent of the bone marrow
Patients with prior wide-field radiotherapy (RT) affecting at least 20 percent of the bone marrow
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OSF Saint Francis Medical Center · Peoria, Illinois
- Massachusetts General Hospital · Boston, Massachusetts
- Tennessee Oncology, PLLC · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06931626 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior wide-field radiotherapy affecting at least 20 percent of the bone marrow disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages